Dataset Information

A Non-Genotoxic Stem Cell Therapy Boosts Lymphopoiesis and Averts Age-Related Blood Diseases in Mice

ABSTRACT: Hematopoietic stem cell (HSC) transplantation can potentially cure various blood disorders, which are especially prevalent among the elderly. However, the high toxicity of conventional conditioning often makes elderly patients ineligible for this treatment. In response, we developed and tested low-intensity conditioning protocols based on antibody-mediated HSC depletion in a murine transplantation model. Initially, we identified significant age-related impediments to effective HSC engraftment. By optimizing HSC doses and a combination of non-toxic targeting methods, we significantly enhanced the long-term multilineage activity of the transplanted cells. We demonstrated that young donor HSCs, once transplanted, not only survive but thrive in aged hosts, dramatically improving hematopoietic output and correcting defective lymphopoiesis. This culminated in a strategy that robustly mitigated disease progression in a genetic model of myelodysplastic syndrome. These results suggest that non-invasive HSC transplantation strategies could fundamentally change the clinical management of age-associated hematological disorders, offering a novel, prophylactic tool to delay or even prevent their onset in elderly patients.

ORGANISM(S): Mus musculus

PROVIDER: GSE267079 | GEO | 2025/04/03

REPOSITORIES: GEO

ACCESS DATA

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Project description:We are studying the natural history, pathogenesis and treatment of patients with WHIM syndrome, an immunodeficiency disorder characterized by warts, hypogammaglobulinemia, recurrent infections and neutropenia usually due to autosomal dominant gain-of-function mutations in chemokine receptor CXCR4. We have identified a patient born with WHIM syndrome and the WHIM mutation CXCR4R334X who has been disease-free for 20 years and who lacks CXCR4R334X in myeloid cells, the cells that drive disease manifestations. She is a genetic and hematopoietic mosaic, since she still has the mutation in lymphoid cells and non-hematopoietic cells. Cytogenetics and microarray analysis revealed that the mechanism of loss of the mutation was deletion of the mutant allele from one copy of chromosome 2. Whole genome sequencing of patient neutrophil and skin fibroblast genomic DNA revealed that the mechanism of deletion was chromothripsis, a process of chromosome shattering resulting in deletions and rearrangements of the non-deleted chromosomal segments. In the patient, this process evidently occurred in a single hematopoietic stem cell (HSC), resulting in deletion of the disease allele CXCR4R334X and one copy of 163 other genes on chromosome 2. This HSC evidently acquired a growth advantage and repopulated the HSC population and the myeloid lineage. Consistent with this, studies using gene targeted mice in competitive bone marrow transplantation experiments revealed that selective Cxcr4 haploinsufficiency (inactivation of one copy of Cxcr4 and not of any other genes) was sufficient to confer a strong engraftment advantage over bone marrow cells from wild type mice as well as bone marrow cells from a mouse model of WHIM syndrome. These results suggest that CXCR4 knockdown may be a useful strategy to enhance bone marrow engraftment in the absence of toxic bone marrow conditioning regimens.

Dataset Information

A Non-Genotoxic Stem Cell Therapy Boosts Lymphopoiesis and Averts Age-Related Blood Diseases in Mice

Dataset's files

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets